Oppenheimer & Co. Inc. increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 39.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,013 shares of the biopharmaceutical company’s stock after purchasing an additional 6,241 shares during the period. Oppenheimer & Co. Inc.’s holdings in Halozyme Therapeutics were worth $2,430,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bank of America Corp DE bought a new position in shares of Halozyme Therapeutics during the second quarter worth $214,504,000. William Blair Investment Management LLC purchased a new stake in Halozyme Therapeutics in the 2nd quarter worth $196,540,000. Jupiter Topco LLC bought a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at about $105,570,000. Caisse de depot et placement du Quebec bought a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at about $83,940,000. Finally, Congress Asset Management Co. boosted its holdings in shares of Halozyme Therapeutics by 85.6% during the 3rd quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock valued at $251,890,000 after purchasing an additional 1,052,509 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.
Insider Transactions at Halozyme Therapeutics
In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total transaction of $2,148,600.00. Following the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $82,482,605.40. This represents a 2.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Posard sold 18,996 shares of the firm’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total value of $2,046,629.04. Following the transaction, the director owned 58,839 shares in the company, valued at approximately $6,339,313.86. This represents a 24.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 125,852 shares of company stock valued at $13,538,046. 2.50% of the stock is currently owned by corporate insiders.
Halozyme Therapeutics Stock Down 0.2%
Shares of NASDAQ:HALO opened at $130.91 on Friday. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $134.00. The stock has a market cap of $14.86 billion, a P/E ratio of 39.08, a price-to-earnings-growth ratio of 0.49 and a beta of 0.88. The business’s 50 day moving average is $113.70 and its 200 day moving average is $83.45. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. Halozyme Therapeutics’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period last year, the business posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 8.31 EPS for the current year.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on HALO shares. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. JPMorgan Chase & Co. increased their price target on Halozyme Therapeutics from $70.00 to $78.00 and gave the company a “neutral” rating in a research note on Thursday, October 8th. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Finally, Citizens Jmp lifted their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $99.55.
Get Our Latest Research Report on Halozyme Therapeutics
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.
Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.
Featured Articles
- Five stocks we like better than Halozyme Therapeutics
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
